Intellia Therapeutics Inc (NASDAQ:NTLA)
| 148.71 BATS BZX Real-Time Price As of 1:55pm ET |  -8.25 / -5.26%Today’s Change | 18.81 Today|||52-Week Range 202.73 | +173.36% Year-to-Date |
Latest NTLA News | Press Releases
| 3 Red-Hot Healthcare Stocks to Buy in September Sep 09 / MotleyFool.com - Paid Partner Content | 3 Hot Stocks to Buy in September Sep 07 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 156.96 |
| Today’s open | 148.98 |
| Day’s range | 146.76 - 153.46 |
| Volume | 17,820 |
| Average volume (3 months) | 1,859,706 |
| Market cap | $11.5B |
Data as of 1:55pm ET, 09/20/2021
Growth & Valuation
| Earnings growth (last year) | -13.81% |
| Earnings growth (this year) | -35.47% |
| Earnings growth (next 5 years) | +7.00% |
| Revenue growth (last year) | +34.55% |
| P/E ratio | NM |
| Price/Sales | 52.52 |
| Price/Book | 19.75 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ZLABZai Lab Ltd | -4.23 | -3.29% |
| CRSPCRISPR Therapeutics ... | -8.20 | -6.59% |
| NBIXNeurocrine Bioscienc... | -0.51 | -0.53% |
| BMRNBiomarin Pharmaceuti... | -0.11 | -0.14% |
Data as of 1:56pm ET, 09/20/2021
Financials
| Next reporting date | November 2, 2021 |
| EPS forecast (this quarter) | -$0.83 |
| Annual revenue (last year) | $58.0M |
| Annual profit (last year) | -$134.2M |
| Net profit margin | -231.46% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
